Most B2B buyers research a manufacturer's specifications, certifications, and pricing—but rarely ask the harder question: who built this company, why does it exist, and what holds it together after 16 years? This is the story of KONGDY Health, why a regional pain patch contract manufacturer in 2010 became a 60-country supplier by 2026, and what that journey means for a buyer evaluating long-term partnership.
Buying pain patches is buying into a relationship that survives customs clearances, regulatory inspections, raw-material shortages, and product reformulations. The story behind the brand tells you whether it's a partnership worth starting.
Every factory has a history. The difference between a manufacturer that lasts two years and one that lasts twenty is the same difference that decides whether your reorder in Q1 will be honored or quietly lost.
Three things a strong origin story reveals:
We share KONGDY's full journey below. Some of it is humbling (early product failures), some of it is fascinating (the 2023 FDA inspection), and most of it is instructive (what it took to scale from 1 country to 60).
KONGDY Health was founded in 2010 in Foshan, Guangdong Province, by three people: a pharmacist (now CEO), a former adhesive engineer from 3M Healthcare (now CTO), and a sales director who'd spent 12 years exporting Chinese medical devices to Europe. The starting capital was modest. The starting ambition was not.
The first cleanroom was 200 square meters. The first production line had 4 stations, hand-assembled. The first order was 80,000 cooling patches for a Vietnamese pharmacy chain—a friendship order from a buyer who trusted the founder personally, not the brand.
What defined those early years was quality discipline over volume. Where other regional contract manufacturers were running 80-hour weeks to fill orders, KONGDY ran 60 hours and spent the other 20 on process documentation. This was the seed of every later achievement.
By 2014, KONGDY had three things most competitors didn't: documented production processes, full batch traceability, and a working quality manual. That's what ISO 13485 audits reward. The certification came in October 2014, audited by TÜV SÜD—a German accreditation body European buyers trust.
The impact was immediate:
ISO 13485 wasn't a marketing checkbox—it was a license to operate at a different level. Looking back, every successful KONGDY contract since 2014 traces to that audit.
The US is the most demanding pain patch market globally—not for product efficacy, but for paperwork. FDA Establishment Registration (FEI) for foreign manufacturers, Drug Listing, UDI assignment, and 21 CFR Part 820 alignment (now moving toward MDR) collectively require 18-24 months of pre-work. KONGDY invested 22 months pre-launch.
The first FDA-registered shipment left Shenzhen port in November 2016—a 30,000-unit private label order for a US sports-recovery brand. The shipment cleared US customs without a single query. The buyer reordered three months later, then quarterly, then bi-monthly.
What US market entry did for KONGDY:
By the end of 2016, KONGDY was exporting to 8 countries. That's the fastest jump in the company's history—from regional to international in 24 months.
The 20-country milestone came in May 2018—and so did KONGDY's first nine-figure-RMB annual contract. A Korean beauty conglomerate signed a 3-year exclusive OEM agreement for a thermal pain patch line targeting East Asian and Southeast Asian markets.
That partnership taught KONGDY three things:
The partnership ended successfully in 2021 when the Korean buyer chose to in-source—exactly the outcome we planned for. They'd grown into a category leader because of our joint work. We've maintained an amicable supplier relationship since.
COVID-19 was the world's stress test—and KONGDY's, too. While many peer factories shut down or pivoted to non-medical products for cash flow, KONGDY tripled production of pain patches. Why? Because the world locked down at home and demand for at-home pain management spiked 220% globally in Q2 2020.
The pivot worked because of pre-pandemic investments:
By end of 2020, KONGDY was exporting to 40 countries—and recorded its first year of >$20M revenue. The pandemic didn't just test us; it accelerated a reputation shift from "regional" to "global."
2023 brought KONGDY's most rigorous third-party audit yet: an FDA Pre-Announced Inspection under the Foreign Supplier Verification Program (FSVP). Three inspectors, four days, 38 person-hours of interviews and document review.
The result: Zero Form 483 observations. Not one procedural gap. Not one documentation fault. The FDA inspector's closing remark, paraphrased: "This is a model facility for overseas suppliers."
What that audit validated to the market:
Within 60 days of the audit, KONGDY signed seven new US distributors. By year-end, North America had become our largest single region.
2024 marked the 50-country crossing. 2026, we serve 60+ countries with 8 regional sales hubs (Shenzhen HQ + EU, North America, LATAM, MENA, ASEAN, Oceania, Sub-Saharan Africa). KONGDY now runs 12 production lines, 5,200 m² of cleanroom space, and a 240-person workforce.
The country distribution:
Continuous investment in capability, not just capacity, defines KONGDY now. We're building a transdermal drug delivery R&D center, expanding into heat-patch and cold-patch adjacencies, and integrating AI-assisted quality control on every production line.
The 60-country scale wasn't built on price. It was built on repeatability. Every buyer in those 60 countries came back, referred another, and stayed. Here's what makes that possible:
Every batch passes HPLC assay, USP microbial testing, peel adhesion, and tensile strength. No exceptions, no "for export-only" quality tiers.
5 million patches/month output, with the ability to flex to 8M for surge orders. KONGDY has fulfilled single orders as large as 2.4 million units in a single month for promotional launches.
Every buyer gets a dedicated account manager fluent in their language and time zone. Average response time: 4 hours. Decision escalation: 24 hours.
Live factory tours via video, real-time production-line cameras, public access to quarterly OTD scores, public CoA standards. You don't need to fly to China to verify us.
Every new market taught us something. The lessons that compounded into our current reputation:
The companies that survive 16 years in this industry aren't the ones that scaled fastest. They're the ones that compounded trust over time. Every year added another 4-6 countries. Every quarter added 2-3 net-new buyers. This is reproducible growth, not viral luck.
The next five years have a clear direction:
Long-term buyers don't just buy today's product—they buy tomorrow's roadmap. KONGDY's roadmap is shared with every partner before each annual review.
A brand story isn't marketing decoration. It's the operating thesis behind every decision the manufacturer makes. At KONGDY Health, our 16-year journey—founding, ISO 13485, FDA entry, 60-country scale, zero-observation audits—exists to answer one question for every prospective buyer: will this company still be here, and still be excellent, in 10 years?
If you're evaluating pain patch suppliers for a long-term private label program, ask not just for certifications but for the story. The factory's past predicts its future behavior. KONGDY's past is documented, audited, and reproducible—and we welcome the scrutiny.
Start a conversation with KONGDY Health today: visit our pain patch catalog or request a no-commitment audit pack.
